|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0003873,
umls-concept:C0005516,
umls-concept:C0008976,
umls-concept:C0243161,
umls-concept:C0678594,
umls-concept:C0949690,
umls-concept:C1519941,
umls-concept:C1527148,
umls-concept:C1547277,
umls-concept:C1749467,
umls-concept:C1883709,
umls-concept:C2349100,
umls-concept:C2349179
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2007-3-8
|
|
pubmed:abstractText |
Recent work has shown that several soluble biomarkers, detectable in peripheral blood, synovial fluid, and/or urine, reflect remodeling of joint tissues and may therefore constitute outcome measures that reflect joint damage. Consequently, it is now desirable to begin the process of developing criteria for validation of a soluble biomarker as an outcome measure reflecting structural damage progression in trials of disease-modifying therapies for rheumatoid arthritis (RA) and spondyloarthritis (SpA). Our objective was to develop validation criteria for a soluble biomarker to be regarded as a valid biomarker reflecting radiological endpoints in RA and SpA clinical trials.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0315-162X
|
|
pubmed:author |
pubmed-author:BoersMaartenM,
pubmed-author:El-GabalawyHaniH,
pubmed-author:GarneroPatrickP,
pubmed-author:GeusensPietP,
pubmed-author:HeinegardDickD,
pubmed-author:KrausVirginia BVB,
pubmed-author:KrauseVirginiaV,
pubmed-author:LandeweRobertR,
pubmed-author:LohmanderStefanS,
pubmed-author:MaksymowychWalter PWP,
pubmed-author:MatyasJohnJ,
pubmed-author:SaxneToreT,
pubmed-author:van der HeijdeDesireeD
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
34
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
634-40
|
|
pubmed:dateRevised |
2008-1-9
|
|
pubmed:meshHeading |
pubmed-meshheading:17343311-Arthritis, Rheumatoid,
pubmed-meshheading:17343311-Biological Markers,
pubmed-meshheading:17343311-Consensus,
pubmed-meshheading:17343311-Delphi Technique,
pubmed-meshheading:17343311-Humans,
pubmed-meshheading:17343311-Outcome Assessment (Health Care),
pubmed-meshheading:17343311-Predictive Value of Tests,
pubmed-meshheading:17343311-Reproducibility of Results,
pubmed-meshheading:17343311-Spondylarthritis,
pubmed-meshheading:17343311-Treatment Outcome
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Development of draft validation criteria for a soluble biomarker to be regarded as a valid biomarker reflecting structural damage endpoints in rheumatoid arthritis and spondyloarthritis clinical trials.
|
|
pubmed:affiliation |
Department of Medicine, University of Alberta, Edmonton, Alberta, Canada. walter.maksymowych@ualberta.ca
|
|
pubmed:publicationType |
Journal Article
|
